B.Sc. Biology, University of Copenhagen, Denmark
M.Sc. Molecular Biology and Biochemistry, University of Copenhagen
Ph.D. Molecular Cancer Biology and Pathology, University of Copenhagen
Senior Research Scientist, Vancouver Prostate Centre
Head, Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre
Assistant Professor, Department of Urologic Sciences, University of British Columbia
Dr. Mads Daugaard is a molecular biologist specialized in tumour-associated stress signaling pathways and tumour targeting systems. He earned his PhD degree from the Faculty of Health Sciences, University of Copenhagen, for his studies on heat shock proteins in relation to cancer cell survival mechanisms. After completing his PhD, Dr. Daugaard received a junior fellowship award to continue his work at the Danish Cancer Society Research Centre on stress signaling pathways related to DNA damage response mechanisms. In 2010, Dr. Daugaard received a research award from the Danish Cancer Society Scientific Committee to do postdoctoral training in molecular pathology at the BC Cancer Research Centre and the Department of Pathology and Laboratory Medicine, University of British Columbia.
In 2014, Dr. Daugaard was recruited to the Vancouver Prostate Centre as a Senior Research Scientist and group leader. His ongoing research focuses on molecular and biochemical events underlying alternative polyadenylation of mRNAs, chromatin context-dependent DNA repair, development of resistance to chemotherapy, and immune-evasion mechanisms in cancer. Another aspect of Dr. Daugaard’s research relates to discovery and development of novel tumour targeting systems based on parasite-derived recombinant proteins relevant for therapeutic and diagnostic applications in cancer.
Dr. Daugaard has published original research in top-tier scientific journals and received competitive international funding support from institutions such as the US Department of Defense (DoD), Canadian Institutes of Health Research (CIHR), Stand Up 2 Cancer (SU2C), and Vancouver Coastal Health Research Institutes (VCHRI). In the 2014 competition, Dr. Daugaard received the Prostate Cancer Canada and Safeway Rising Star Award. Dr. Daugaard has served as an Editor of Cell Death & Disease (Nature Publishing Group) since 2016.
In 2012, Dr. Daugaard co-founded the biotechnology companies VAR2 Pharmaceuticals and OncoMal, and in 2017, the diagnostic company VarCT Diagnostics. Dr. Daugaard is elected Chairman of the Board of Directors in all three companies.